Nuvalent, Inc. (NUVL) saw a 14.24% surge to $110.24 after reporting strong topline data from its ALKOVE-1 trial for neladalkib in ALK-positive NSCLC patients. Response rates and durability showed significant improvements, positioning neladalkib as a potential best-in-class ALK inhibitor in a heavily pretreated setting. This news excited investors and led to heavy trading volume in NUVL shares. The stock’s 52-week range is $55.30 – $110.24.

Read more at Nasdaq: Nuvalent Shares Jump 14% After Positive Pivotal ALKOVE-1 Trial Results In ALK-Positive NSCLC